Glenmark Pharmaceuticals has announced their newest fixed-dose combination (FDC) Zita Plus Pio, which will help patients with uncontrolled Type 2 diabetes. The FDC, containing Teneligliptin, with Pioglitazone, is a first-of-its-kind dose and help reduce insulin resistance by having better control over glycemic index among adults.
Glenmark has claimed that it is the first company to have developed this product, which has also been approved by Drug Controller General of India (DCGI). The group’s Vice President & Head, India Formulations Alok Malik asserted, “We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients.”
Diabetes is being considered as a global epidemic and India ranks second in number of patients, only after China. Currently, 25.2 million adults are estimated to be suffering from this life-style disease , which is likely to increase to 35.7 million by 2045. Many of these patients have to take high dosages of drugs to maintain and improve their gliycemic control.
“This fixed-dose combination will be useful for patients who require treatment with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control reducing insulin resistance,” the company said.
